首页 > 专栏 > The Lancet Diabetes & Endocrinology The Lancet Diabetes & Endocrinology 共 37 条资讯 [Comment] What Mauritius teaches us about diabetes surveillance 2026-06-28 11:43:57 [Articles] Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study 2026-06-28 11:43:57 [Editorial] Safeguarding paediatric metabolic health 2026-06-28 11:43:57 [Review] Diabetes and the role of primary care: a global perspective 2026-06-28 11:43:57 [Personal View] Disease modification outcomes in type 2 diabetes: a modified Delphi 2026-06-28 11:43:57 [Comment] Petrelintide and the evolving role of amylin agonism in obesity 2026-06-28 11:43:57 [Articles] Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial 2026-06-28 11:43:57 [Review] New genomic understanding and challenges in clinical care of Turner syndrome 2026-06-28 11:43:57 [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13 2026-06-28 11:43:57 [Corrections] Correction to Lancet Diabetes Endocrinol 2026; 14: 149–56 2026-06-28 11:43:57 [Review] Hypoparathyroidism: translating science from the laboratory to the clinic 2026-06-28 11:43:57 [Articles] Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case–control study 2026-06-28 11:43:57 [Review] From adiposity to multisystem morbidity: the case for weight loss as disease modification 2026-06-28 11:43:57 [Correspondence] Time for personalised incretin titration 2026-06-28 11:43:57 [Comment] The glucagon renaissance in obesity therapeutics 2026-06-28 11:43:57 [Articles] Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial 2026-06-28 11:43:57 [Editorial] Diabetes in a warming world 2026-06-28 11:43:57 [Comment] Safety and tolerability of orforglipron in Japanese people with type 2 diabetes 2026-06-28 11:43:57 [Articles] Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial 2026-06-28 11:43:57 [In Focus] Toxic chemicals: the fight for planetary health 2026-06-28 11:43:57 12下一页 » 相关分类 The Lancet Diabetes & Endocrinology The Lancet #!/slash/note #UNTAG (B)(F)uzzing on my world (Hi)story (IN)SECURE Magazine Notification (gdb) break *0x972 - 带鱼博客 BeltfishBlog - ./kwaa.dev .NET Blog .Trash /home/rook1e 00's Adventure 0kami's Blog 0x41414141 in ?? () 0x7f Blog 0xRick Owned Root ! 0xd00's blog 1 Byte 1A23 Blog 1A23 Studio 1Link.Fun 1stwebdesigner 251 2BAB 的工程博客 2ch中文网 360 CERT 360 Netlab Blog - Network Securi 38号车评中心